ClinicalTrials.Veeva

Menu

Influence of Intraoperative Blood Salvage and Autotransfusion on Tumor Recurrence After Deceased Donor Liver Transplantation

Zhejiang University logo

Zhejiang University

Status

Completed

Conditions

Liver Transplant; Complications

Study type

Observational

Funder types

Other

Identifiers

NCT06307158
CT2024-ZJU-OBS1

Details and patient eligibility

About

The practice of intraoperative blood salvage and autotransfusion (IBSA) during deceased donor liver transplantation (DDLT) for hepatocellular carcinoma (HCC) can potentially reduce the need for allogeneic blood transfusion. However, implementing IBSA remains debatable due to concerns about its possible detrimental effects on oncologic recurrence. Hence, a nationwide multi-center study was conducted to investigate further the association between IBSA and post-transplant HCC recurrence, including a stratified subgroup analysis.

Enrollment

998 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • adult-to-adult deceased donor liver transplantation for hepatocellular carcinoma

Exclusion criteria

  • patients under 18 years of age
  • presence of extrahepatic metastasis
  • combined kidney transplantation
  • reduced-size or split liver transplantation
  • re-transplantation

Trial design

998 participants in 2 patient groups

Intraoperative blood salvage and autotransfusion (IBSA) group
Description:
The study included patients who underwent adult-to-adult DDLT for HCC in China between January 2015 and December 2020. Exclusion criteria included: patients under 18 years of age, presence of extrahepatic metastasis, combined kidney transplantation, reduced-size or split liver transplantation, re-transplantation, and missing data on analyzed variables. The remaining recipients were 349 in IBSA group who received salvaged blood autotransfusion during the LT.
non-intraoperative blood salvage and autotransfusion (non-IBSA) group
Description:
The study included patients who underwent adult-to-adult DDLT for HCC in China between January 2015 and December 2020. Exclusion criteria was as mentioned ahead. Recipients who did not receive salvaged blood autotransfusion during the LT were enrolled in non-IBSA group.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems